# Nexentis Technologies Inc.: overview

NXTS · Nasdaq · CIK 1789192 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nxts.md) · [Financials](/companies/nxts/financials.md) · [Filings](/companies/nxts/filings.md) · [Insiders](/companies/nxts/insiders.md)

Latest reported revenue: [$2.0k](/filings/0001493152-25-022355.md) for Q3 FY2025, three months to 2025-09-30, from the 10-Q filed Nov 13, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-25-022355).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [9.0](/filings/0001493152-25-022355.md) | [141 d](/filings/0001641172-25-001513.md) | [66.0](/filings/0001641172-25-010883.md) | [0.0 d](/filings/0001493152-25-011990.md) | [2.0](/filings/0001493152-25-022355.md) | not reported | not reported | not reported |
| Gross margin | % | [(755.6%)](/filings/0001493152-25-022355.md) | [61.0% d](/filings/0001641172-25-001513.md) | [78.8%](/filings/0001641172-25-010883.md) | not reported | [0.0% d](/filings/0001493152-25-022355.md) | not reported | not reported | not reported |
| Operating margin | % | [(15955.6%)](/filings/0001493152-25-022355.md) | [(155.3%) d](/filings/0001493152-26-014183.md) | [(762.1%)](/filings/0001493152-26-023107.md) | not reported | [(66300.0%)](/filings/0001493152-25-022355.md) | not reported | not reported | not reported |
| Net margin | % | [(25155.6%)](/filings/0001493152-25-022355.md) | [(973.8%) d](/filings/0001493152-26-014183.md) | [(1807.6%)](/filings/0001493152-26-023107.md) | not reported | [21450.0%](/filings/0001493152-25-022355.md) | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.39)](/filings/0001493152-24-045890.md) | not reported | [(85.25)](/filings/0001493152-26-023107.md) | [(44.26)](/filings/0001493152-26-037757.md) | [0.97](/filings/0001493152-25-022355.md) | not reported | [(10.74)](/filings/0001493152-26-023107.md) | [(13.66)](/filings/0001493152-26-037757.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | [(1,490)](/filings/0001493152-26-023107.md) | [(540) d](/filings/0001493152-26-037757.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [438](/filings/0001493152-23-009116.md) | [394](/filings/0001493152-24-012356.md) | [263](/filings/0001641172-25-001513.md) | [210](/filings/0001641172-25-001513.md) | not reported |
| Gross margin | % | [69.0%](/filings/0001493152-23-009116.md) | [59.8%](/filings/0001493152-24-012356.md) | [79.1%](/filings/0001641172-25-001513.md) | [21.4%](/filings/0001641172-25-001513.md) | not reported |
| Operating margin | % | [(1073.5%)](/filings/0001493152-23-009116.md) | [(1477.1%)](/filings/0001493152-24-012356.md) | [(2881.4%)](/filings/0001641172-25-001513.md) | [(1563.3%)](/filings/0001493152-26-014183.md) | not reported |
| Net margin | % | [(1100.2%)](/filings/0001493152-23-009116.md) | [(1456.7%)](/filings/0001493152-24-012356.md) | [(2479.8%)](/filings/0001641172-25-001513.md) | [(2472.9%)](/filings/0001493152-26-014183.md) | not reported |
| Diluted EPS | $ per share | [(2.06)](/filings/0001493152-22-008526.md) | [10.85](/filings/0001493152-24-012356.md) | [(5.43)](/filings/0001641172-25-001513.md) | [(27.74)](/filings/0001493152-26-014183.md) | [(8.61)](/filings/0001493152-26-014183.md) |
| Free cash flow | $k | [(4,181)](/filings/0001493152-23-009116.md) | [(5,149)](/filings/0001493152-24-012356.md) | not reported | not reported | [(3,822)](/filings/0001493152-26-014183.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nxts/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Yorkville Advisors Global, LP](/funds/1838613.md) | 2026-06-30 | $70.7k | 16,409 |  | New +16,409 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $4.3k | 998 |  | New +998 |
| [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.2k | 736 |  | New +736 |
| [HRT FINANCIAL LP](/funds/1475597.md) | 2026-06-30 | $194 | 45,240 |  | New +45,240 |
| [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $138 | 32 |  | Reduced −26 |
| [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $4 | 1 |  | New +1 |

## Recent filings

[All 309 filings](/companies/nxts/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 20:05 ET | [8-K](/filings/0001493152-26-047578.md) | 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors | 0001493152-26-047578 |
| 2026-10-06 | 13:30 ET | [8-K](/filings/0001493152-26-045885.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-045885 |
| 2026-09-03 | 20:05 ET | [8-K](/filings/0001493152-26-041358.md) | 3.01 Delisting notice | 0001493152-26-041358 |
| 2026-08-13 | 20:06 ET | [10-Q](/filings/0001493152-26-037757.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037757 |
| 2026-08-06 | 20:06 ET | [8-K](/filings/0001493152-26-036335.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001493152-26-036335 |
| 2026-07-13 | 20:05 ET | [S-1](/filings/0001493152-26-033026.md) | Registration statement | 0001493152-26-033026 |
| 2026-06-22 | 20:49 ET | [8-K](/filings/0001493152-26-029611.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-029611 |
| 2026-06-12 | 20:15 ET | [8-K](/filings/0001493152-26-028439.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-26-028439 |
| 2026-05-27 | 20:05 ET | [8-K](/filings/0001493152-26-025397.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001493152-26-025397 |
| 2026-05-14 | 20:21 ET | [10-Q](/filings/0001493152-26-023107.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023107 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-014183.md), filed Mar 31, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1789192
- Tickers: NXTS
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: NV
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.